Article

Approval No. 5 for Avastin

Author(s):

You can officially add Avastin to the list of targeted drugs approved for kidney cancer. Genentech just reported that the Food and Drug Administration has approved Avastin (bevacizumab) plus interferon for patients with metastatic renal cell carcinoma, the most common type of kidney cancer. (Check out our feature on kidney cancer from the current Summer issue.) That's the fifth cancer for which the FDA has deemed Avastin worthy of its stamp of approval. Just this past May, the regulatory agency greenlighted the drug for a type of brain tumor called glioblastoma multiforme, and before that, Avastin was OKed for metastatic colorectal cancer, non-small cell lung cancer, and metastatic breast cancer. (Its first approval came in 2004.)We'll cover the approval in more detail in the upcoming Fall issue, which drops in September.

Related Videos
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Related Content